David Westenberg
Stock Analyst at Piper Sandler
(4.42)
# 358
Out of 5,014 analysts
175
Total ratings
55.45%
Success rate
18.86%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXAS Exact Sciences | Maintains: Overweight | $60 → $70 | $60.15 | +16.38% | 12 | Oct 8, 2025 | |
| WGS GeneDx Holdings | Maintains: Overweight | $120 → $140 | $130.86 | +6.98% | 3 | Sep 11, 2025 | |
| TXG 10x Genomics | Initiates: Neutral | $15 | $12.10 | +23.97% | 2 | Sep 11, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $1.25 → $1.5 | $1.59 | -5.66% | 9 | Aug 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $210 → $215 | $144.47 | +48.82% | 15 | Aug 11, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $510 → $700 | $624.88 | +12.02% | 11 | Aug 11, 2025 | |
| ELAN Elanco Animal Health | Maintains: Neutral | $12 → $18 | $20.36 | -11.59% | 10 | Aug 11, 2025 | |
| NTRA Natera | Maintains: Overweight | $210 → $220 | $173.79 | +26.59% | 16 | Aug 11, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $13 → $15 | $15.58 | -3.69% | 14 | Aug 6, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $12 → $11 | $9.09 | +21.01% | 10 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $21 | $23.05 | -8.89% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $70 | $102.87 | -31.95% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $185 | $98.43 | +87.95% | 16 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $260 → $280 | $279.44 | +0.20% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $66.36 | -9.58% | 9 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $200 | $181.83 | +9.99% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.4 → $5 | $7.05 | -29.08% | 12 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8.5 → $8 | $3.96 | +102.02% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $27.99 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $42.15 | - | 1 | Nov 21, 2017 |
Exact Sciences
Oct 8, 2025
Maintains: Overweight
Price Target: $60 → $70
Current: $60.15
Upside: +16.38%
GeneDx Holdings
Sep 11, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $130.86
Upside: +6.98%
10x Genomics
Sep 11, 2025
Initiates: Neutral
Price Target: $15
Current: $12.10
Upside: +23.97%
Pacific Biosciences of California
Aug 11, 2025
Maintains: Neutral
Price Target: $1.25 → $1.5
Current: $1.59
Upside: -5.66%
Zoetis
Aug 11, 2025
Maintains: Overweight
Price Target: $210 → $215
Current: $144.47
Upside: +48.82%
IDEXX Laboratories
Aug 11, 2025
Maintains: Neutral
Price Target: $510 → $700
Current: $624.88
Upside: +12.02%
Elanco Animal Health
Aug 11, 2025
Maintains: Neutral
Price Target: $12 → $18
Current: $20.36
Upside: -11.59%
Natera
Aug 11, 2025
Maintains: Overweight
Price Target: $210 → $220
Current: $173.79
Upside: +26.59%
Adaptive Biotechnologies
Aug 6, 2025
Maintains: Overweight
Price Target: $13 → $15
Current: $15.58
Upside: -3.69%
NeoGenomics
Aug 4, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $9.09
Upside: +21.01%
Aug 4, 2025
Maintains: Neutral
Price Target: $23 → $21
Current: $23.05
Upside: -8.89%
May 15, 2025
Maintains: Neutral
Price Target: $55 → $70
Current: $102.87
Upside: -31.95%
May 15, 2025
Maintains: Overweight
Price Target: $190 → $185
Current: $98.43
Upside: +87.95%
May 6, 2025
Maintains: Neutral
Price Target: $260 → $280
Current: $279.44
Upside: +0.20%
May 6, 2025
Maintains: Overweight
Price Target: $50 → $60
Current: $66.36
Upside: -9.58%
Apr 28, 2025
Maintains: Neutral
Price Target: $180 → $200
Current: $181.83
Upside: +9.99%
Apr 22, 2025
Maintains: Neutral
Price Target: $6.4 → $5
Current: $7.05
Upside: -29.08%
Mar 4, 2025
Maintains: Overweight
Price Target: $8.5 → $8
Current: $3.96
Upside: +102.02%
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $27.99
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $42.15
Upside: -